Drug Profile
ADCT 502 - ADC Therapeutics
Alternative Names: ADCT 502 ADC TherapeuticsLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator ADC Therapeutics; Cancer Research Technology
- Developer ADC Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 04 May 2018 ADC Therapeutics terminates a phase I trial in Solid tumours in USA due to safety reasons (NCT03125200)
- 17 Apr 2017 Phase-I clinical trials in Solid tumours in USA (IV) (NCT03125200)